Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

CAR-T Meeting 2021 and Car T Meeting 2021 View overview page

2:41
Myeloma Patients Europe: collaborating on projects to benefit the myeloma community
Ananda Plate • 11 Feb 2021
3:41
The importance of partnering with patient organizations
Ananda Plate • 11 Feb 2021
1:45
CAR T-cells in myeloma: patients’ perspective
Ananda Plate • 11 Feb 2021
6:02
CAR-T vs. BiTEs in B-cell malignancies
Marion Subklewe • 11 Feb 2021
1:04
The major hurdles and emerging opportunities of CAR T-cell therapy
Sara Ghorashian • 4 Feb 2021
1:13
CAR-T nursing education
Erik Aerts • 4 Feb 2021
3:51
Universal “off-the-shelf” CAR T-cells from iPSCs
Alexandros Nianias • 6 Feb 2021
4:10
The challenges of CAR T-cell therapy for pediatric B-ALL
Sara Ghorashian • 4 Feb 2021
4:58
Impact of spleen size and splenectomy on outcomes of allo-HSCT for myelofibrosis
Ibrahim Yakoub-Agha • 4 Feb 2021
1:43
Management of CAR-T related side effects
Ibrahim Yakoub-Agha • 4 Feb 2021
1:34
NK-CAR immunotherapy: where are we now?
Concetta Quintarelli • 4 Feb 2021
1:05
ARI-0001 in CD19+ malignancies: next steps
Valentín Ortiz-Maldonado • 3 Feb 2021
1:08
CAR-T therapy: treatment burden and costs
Erik Aerts • 4 Feb 2021
3:23
Second CD19-targeted CAR T-cell infusion for R/R B-cell malignancies
Jordan Gauthier • 28 Jan 2021
1:40
Regulatory considerations for CAR-T academic trials
Manel Juan Otero • 25 Jan 2021
1:43
Collaboration in the field of cellular therapies
Sofie Terwel • 28 Jan 2021
The content of VJHemOnc is intended for healthcare professionals